NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Sanofi SNY
11 fiscal years on record · EUR · FY2025 reported
SEC FILINGS ONLY10 YEARS OF DIVIDEND GROWTH
Revenue · FY2025
€43.6B
▲ 6.2% vs FY2024
Dividend streak
10 yrs
Raised every year since 2016
EPS · FY25
€6.37
Dividend / sh · FY25
€3.92
Payout · FY25
61%
ROE · FY25
10.5%
Net margin · FY25
17.9%
Dividend coverage
1.6×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
EUR 43.6B
Revenue, FY2025 · full 11-year series below
Revenue
Net income
18 cents of every revenue dollar became profit this year.
Per share
EUR 6.37
Diluted EPS, FY2025
EPS
Dividend
Earnings covered the dividend 1.6 times — the rest stayed in the company.
Profitability
10.5%
Return on equity, FY2025
ROE
Operating margin14.5%
Net margin17.9%
Return on assets6.0%
Each EUR of equity produced 10 cents of profit this year.
Returned to shareholders
EUR 9.8B
returned in FY2025 · dividends + net buybacks
Dividends paidEUR 4.8B
Net buybacksEUR 5.0B
Share of profit125.5%
Consecutive raises10 years
EUR 4.8B in dividends and EUR 5.0B in buybacks — 125% of the year's profit, so the payout drew on cash built up earlier.
Growth
+3.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+5.0%
+3.9%
+2.5%
Net income
−2.3%
−8.7%
+6.2%
EPS, diluted
−1.5%
−8.2%
+7.0%
Dividend / share
+5.6%
+4.5%
+3.2%
Returned to shareholders
+28.1%
+15.5%
+6.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
EUR 126.8B
total assets, end of FY2025
Total assetsEUR 126.8B
EquityEUR 71.4B
CashEUR 7.7B
Gross debtEUR 18.7B
Net debtEUR 11.0B
Current ratio1.09×
Net debt stands at 15% of equity.
History
11 fiscal years
Every figure from documents filed with the SEC · EUR
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
Revenue €B
43.6
41.1
37.8
37.7
37.8
36.0
36.1
34.5
35.1
33.8
34.1
Operating income €B
6.3
7.3
7.0
10.2
8.1
14.1
3.1
4.7
5.8
6.5
5.6
EBITDA €B
·
·
·
·
·
·
·
·
·
·
·
Income tax €B
1.0
1.2
1.0
1.9
1.6
1.8
0.1
0.5
1.7
1.3
0.7
Net income €B
7.8
5.6
5.4
8.4
6.2
12.3
2.8
4.3
8.4
4.7
4.3
EPS, diluted €
6.37
4.43
4.30
6.66
4.95
9.76
2.27
3.43
6.64
3.63
3.25
Dividend / sh €
3.92
3.76
3.56
3.33
3.20
3.15
3.07
3.03
2.96
2.93
2.85
Payout %
61
85
82
50
64
32
139
88
44
80
86
ROE %
10.5
7.3
7.3
11.7
9.4
20.1
4.7
7.4
14.6
8.1
7.4
Shares out B
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
26 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 11 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed